Veritas becomes exclusive distributor in Japan for Epistem

Will enable Epistem to extend its research services in the region

Japanese life science products distributor Veritas is to become the exclusive distributor of Epistem’s contract research services in Japan.

UK-based Epistem provides preclinical and scientific research services to drug development and personal care companies specialising in the areas of oncology, mucositis, inflammatory bowel disease, wound healing and skincare.

The company already has a customer base in Western Europe and the US. It says the agreement with Veritas will provide a sales and marketing presence in Japan to help extend its research services within the region.

Epistem’s chief executive Matthew Walls said: ‘The Japanese drug development market provides us with an important opportunity for growth and the agreement with Veritas will allow us to develop closer links with existing Japanese customers.’

Sinsaku Lida, ceo of Veritas, added: ‘Epistem's contract research division has a strong preclinical and scientific research service capability, which will benefit Japanese pharmaceutical and personal care companies.

‘Veritas’ sales network has the scientific experience necessary to introduce Epistem's high quality services to potential Japanese customers.’